Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03684980 · ClinicalTrials.gov registry record · Early Phase 1
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
A Early Phase 1 study of Central Nervous System Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 58
- Enrollment target
- 11
- Study locations
NCT03684980: Active Early Phase 1 study of Central Nervous System Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03684980 is a Early Phase 1 study of Central Nervous System Lymphoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 58 participants, below the 101-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (43% lower). The trial reports 11 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03684980, a Early Phase 1 study of Central Nervous System Lymphoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 58 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.
Primary Outcome
All serum samples will be tested via MTX immunoassay (measures MTX levels in addition to byproducts) as well as HPLC or mass spectroscopy which will reveal plasma concentrations of MTX and DAMPA separately.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Methotrexate
- DRUG leucovorin
- DRUG Glucarpidase
Study Locations (11)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Cleveland Clinic (Data Collection and Specimen Collection) - Cleveland
Alabama
- University of Alabama at Birmingham - Birmingham
Massachusetts
- Dana Farber Cancer Institute (Data Collection and Specimen Analysis) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2018-11-14 |
| Est. Completion | 2027-11 |
| Phase | Early Phase 1 |
What the registry record for NCT03684980 still lists
NCT03684980 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 101-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Central Nervous System Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Rituximab is the first listed.
NCT03684980 lists 11 locations in 5 states (New York, New Jersey, Ohio).
Frequently Asked Questions
What is clinical trial NCT03684980 about?
NCT03684980 is a clinical study titled "LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma". The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.
What is the current status of trial NCT03684980?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 58 participants. The study started on 2018-11-14. Estimated completion is 2027-11.
What conditions does trial NCT03684980 study?
This clinical trial studies the following conditions: Central Nervous System Lymphoma.
What interventions are being tested in trial NCT03684980?
The interventions under investigation include: Rituximab (DRUG), Methotrexate (DRUG), leucovorin (DRUG), Glucarpidase (DRUG).
Who is sponsoring clinical trial NCT03684980?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03684980 being conducted?
This trial has 11 study locations across Alabama, Massachusetts, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03684980's enrollment target sits among peer trials
58 7th of 14 higher than 8 of 14 other Central Nervous System Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Central Nervous System Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
RECRUITING · Phase 1
-
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
RECRUITING · Phase 1
-
DALY II USA/ MB-CART2019.1 for DLBCL
RECRUITING · Phase 2
-
Long-term Follow-up Study of Patients Receiving CAR-T Cells
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI